|Bid||316.99 x 1000|
|Ask||317.78 x 900|
|Day's Range||314.36 - 318.42|
|52 Week Range||191.39 - 335.99|
|PE Ratio (TTM)||28.04|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||1.20 (0.38%)|
|1y Target Est||330.50|
Chemed Corporation (NYSE:CHE), a healthcare company based in United States, maintained its current share price over the past couple of month on the NYSE, with a relatively tight range ofRead More...
The home health industry is poised for tremendous growth driven by the growing geriatric U.S. population, the prevalence of chronic illness, high cost of treatment at inpatient settings and increased use of home healthcare technologies. Also, continued pressure on the U.S. healthcare system to control cost will lead to a shift in care from higher-cost institutional in patient care settings to a lower-cost environment such as home health and outpatient locations. Per Garden View Research, home healthcare is a cost efficient alternative to expensive hospital stays.
Growing senior population, increasing chronic illness, high cost of treatment at inpatient settings and preference by patients drives demand for home health care.
Chemed (CHE) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.